Fecal microbiota transplantation (FMT) is an innovative therapy already used in humans to treat Clostridioides difficile infections associated with massive use of antibiotics. Clinical studies are obviously the gold standard to evaluate FMT efficiency but remain limited by regulatory, ethics, and cost constraints. In the present study, an in vitro model of the human colon reproducing medically relevant perturbation of the colonic ecosystem by antibiotherapy was used to compare the efficiency of traditional FMT enema formulations and a new oral capsule in restoring gut microbiota composition and activity. Loss of microbial diversity, shift in bacterial populations, and sharp decrease in fermentation activities induced in vivo by antibiotherapy were efficiently reproduced in the in vitro model, while capturing inter-individual variability of gut microbiome. Oral capsule was as efficient as enema to decrease the number of disturbed days and bacterial load had no effect on enema performance. This study shows the relevance of human colon models as an alternative approach to in vivo assays during preclinical studies for evaluating FMT efficiency. The potential of this in vitro approach could be extended to FMT testing in the management of many digestive or extra-intestinal pathologies where gut microbial dysbiosis has been evidenced such as inflammatory bowel diseases, obesity or cancers.
AbstractBackground
Fecal microbiota transfer (FMT) is an innovative treatment already successfully used in recurrent Clostridioides difficile infections. Researchers and clinicians are exploring its potential for treating other digestive or extra-intestinal pathologies where gut microbial dysbiosis has been evidenced, such as inflammatory bowel disease, obesity or cancers. Oral capsules were recently developed to address gaps of traditional routes of FMT such as enema or colonoscopy. Clinical studies are obviously the gold standard to evaluate FMT efficiency but remain limited by regulatory, ethics and cost constraints. The aim of the study was to use the in vitro human Artificial Colon ARCOL to compare the efficiency of two enema dosage (10 and 30 g) and a new oral caecum-release capsule in restoring gut microbiota composition and activity after treatment with ciprofloxacin, an antibiotic used in leukemia patients.
Results
By integrating the main physicochemical parameters of the human colon (pH, retention time, nutrient supply and anaerobiosis), ARCOL was shown to capture microbial diversity and inter-individual variability of stools from three healthy donors. Treatment with ciprofloxacin led to a state of marked dysbiosis with a sharp decrease in fermentation activities (production of gases and short chain fatty acids), a loss of microbial diversity and a shift in bacterial populations. All FMT treatments were able to speed-up the restoration of microbial profiles and functions, by decreasing the number of dysbiotic days from 12 to 7–8 depending on the FMT modes. Of note, the bacterial load showed no major influence on enema performance, and oral capsule was almost as efficient as enema even if the amount of administered bacteria was 100 times lower.
Conclusions
This study provides the first example of using an in vitro human colon model for evaluating autologous FMT efficiency and highlights the potential of oral capsule compared to a traditional enema formulation. This new mode of FMT administration combines efficiency with convenient and minimally invasive mode of administration. In accordance to 3R rules, gut models like ARCOL can be advantageously used to test FMT in preclinical phases as an alternative to in vivo assays.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.